370) eosinophils in naïve mice within 2 h of treatment, accompanied by an increase in I |
371) rther, to gain traction on prevention and treatment, additional research to identify |
372) SC trastuzumab are equivalent in terms of treatment-emergent adverse events (TEAEs) |
373) nce it makes a compromise between optimal treatment allocation and randomness with s |
374) vitro and in vivo, as compared to either treatment alone. |
375) Further, alcohol treatment also led to the induction of syn |
376) barrier to engaging in HIV prevention and treatment among both HIV-negative and HIV- |
377) s: (a) family disagreements over curative treatment and/or end-of-life care and deci |
378) Conventional treatment approaches, such as surgery, che |
379) and psychosexual adjustment after cancer treatment are needed. |
380) Ambient/room temperature settings in burn treatment areas vary greatly due to a lack |
381) Adherence was assessed by the treatment attendance rates, and maintenanc |
382) uentially allocating patients to the best treatment based on the responses of patien |
383) X5 to be an oncogenic target and a cancer treatment-resistant biomarker, a few studi |
384) eview identified preliminary evidence for treatment-dependent brain changes in adult |
385) way to assess the clinical efficacy of a treatment by combining the results of rand |
386) However, before incorporation into treatment can occur, there is a need for r |
387) been researched to support Canadian post-treatment cancer survivors; and (2) analyz |
388) derstanding of each stage of the 90:90:90 treatment cascade (as proposed by UNAIDS), |
389) s from tumor and tumor-adjacent tissue of treatment-naive ccRCC resections. |
390) , study characteristics and day programme treatment characteristics, then narrativel |
391) ds were evaluated for factors influencing treatment choices, with particular attenti |
392) 10 studies, 37 (34%) included a nutrition treatment component. |
393) any of the treatments consisted of common treatment components occurring in both net |
394) Treatment comprises conservative treatment |
395) A and/or DHA supplementation pre- or post-treatment, concomitant with neoadjuvant ch |
396) e is used to relate outcome to period and treatment condition. |
397) ors (e.g., adverse reactions, duration of treatment, cost of treatment), and patient |
398) With mental health-related treatment costs and economic burden only p |
399) sed to evaluate if and how corticosteroid treatment could influence disease outcome |
400) ta-analyses (NMAs) increasingly assist in treatment decisions in disease areas such |
401) The treatment decreased prolyl hydroxylation, |
402) Loss to follow-up and treatment delays could be addressed by imp |
|